These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

331 related articles for article (PubMed ID: 28267636)

  • 1. Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Ryder SA; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; D'Arcy DM; McHugh J
    Clin Microbiol Infect; 2017 Sep; 23(9):674.e7-674.e13. PubMed ID: 28267636
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.
    Byrne CJ; Parton T; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Enright H; Desmond R; Ryder SA; D'Arcy DM; McHugh J; Roberts JA
    J Antimicrob Chemother; 2018 Apr; 73(4):995-1003. PubMed ID: 29272419
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.
    Zhao W; Zhang D; Storme T; Baruchel A; Declèves X; Jacqz-Aigrain E
    Br J Clin Pharmacol; 2015 Nov; 80(5):1197-207. PubMed ID: 26138279
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Population pharmacokinetics of teicoplanin in children.
    Ramos-Martín V; Paulus S; Siner S; Scott E; Padmore K; Newland P; Drew RJ; Felton TW; Docobo-Pérez F; Pizer B; Pea F; Peak M; Turner MA; Beresford MW; Hope WW
    Antimicrob Agents Chemother; 2014 Nov; 58(11):6920-7. PubMed ID: 25224001
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy.
    Byrne CJ; Roberts JA; McWhinney B; Fennell JP; O'Byrne P; Deasy E; Egan S; Desmond R; Enright H; Ryder SA; D'Arcy DM; McHugh J
    Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28320714
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Population Pharmacokinetics of Teicoplanin in Preterm and Term Neonates: Is It Time for a New Dosing Regimen?
    Kontou A; Sarafidis K; Begou O; Gika HG; Tsiligiannis A; Ogungbenro K; Dokoumetzidis A; Agakidou E; Roilides E
    Antimicrob Agents Chemother; 2020 Mar; 64(4):. PubMed ID: 31932366
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Population Pharmacokinetics and Pharmacodynamics of Teicoplanin and C-Reactive Protein in Hospitalized Patients With Gram-Positive Infections.
    Ogami C; Tsuji Y; Muraki Y; Mizoguchi A; Okuda M; To H
    Clin Pharmacol Drug Dev; 2020 Feb; 9(2):175-188. PubMed ID: 30934169
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections.
    Wang JT; Liao HI; Wu Lin FL; Chang SC
    Basic Clin Pharmacol Toxicol; 2012 May; 110(5):416-20. PubMed ID: 22309355
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetics of teicoplanin administered by subcutaneous or intravenous route and simulation of optimal loading dose regimen.
    Cazaubon Y; Venisse N; Mimoz O; Maire P; Ducher M; Bourguignon L; Goutelle S
    J Antimicrob Chemother; 2017 Oct; 72(10):2804-2812. PubMed ID: 29091222
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Population pharmacokinetic analysis and dosing regimen optimization of teicoplanin in critically ill patients with sepsis.
    Chen CY; Xie M; Gong J; Yu N; Wei R; Lei LL; Zhao SM; Li RM; Dong X; Zhang XL; Zhou Y; Li SL; Cui YM
    Front Pharmacol; 2023; 14():1132367. PubMed ID: 37188268
    [No Abstract]   [Full Text] [Related]  

  • 11. Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.
    Byrne CJ; Egan S; Fennell JP; O'Byrne P; Enright H; Deasy E; Ryder SA; D'Arcy DM; McHugh J
    Int J Antimicrob Agents; 2015 Oct; 46(4):406-12. PubMed ID: 26228465
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Ampicillin in Neonates with Hypoxemic-Ischemic Encephalopathy in the Setting of Controlled Hypothermia.
    Cies JJ; Fugarolas KN; Moore WS; Mason RW; Menkiti OR
    Pharmacotherapy; 2017 Apr; 37(4):456-463. PubMed ID: 28226400
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Optimal Teicoplanin Dosage Regimens in Critically Ill Patients: Population Pharmacokinetics and Dosing Simulations Based on Renal Function and Infection Type.
    Wang Y; Yao F; Chen S; Ouyang X; Lan J; Wu Z; Wang Y; Chen J; Wang X; Chen C
    Drug Des Devel Ther; 2023; 17():2259-2271. PubMed ID: 37546521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population Pharmacokinetics and Pharmacodynamic Target Attainment of Vancomycin in Neonates on Extracorporeal Life Support.
    Cies JJ; Moore WS; Nichols K; Knoderer CA; Carella DM; Chopra A
    Pediatr Crit Care Med; 2017 Oct; 18(10):977-985. PubMed ID: 28650363
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Population Pharmacokinetics and Dose Optimization of Teicoplanin during Venoarterial Extracorporeal Membrane Oxygenation.
    Wi J; Noh H; Min KL; Yang S; Jin BH; Hahn J; Bae SK; Kim J; Park MS; Choi D; Chang MJ
    Antimicrob Agents Chemother; 2017 Sep; 61(9):. PubMed ID: 28674057
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Simplified dosing regimens of teicoplanin for patient groups stratified by renal function and weight using Monte Carlo simulation.
    Yamada T; Nonaka T; Yano T; Kubota T; Egashira N; Kawashiri T; Oishi R
    Int J Antimicrob Agents; 2012 Oct; 40(4):344-8. PubMed ID: 22818770
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Population Pharmacokinetics of Unbound and Total Teicoplanin in Critically Ill Pediatric Patients.
    Aulin LBS; De Paepe P; Dhont E; de Jaeger A; Vande Walle J; Vandenberghe W; McWhinney BC; Ungerer JPJ; van Hasselt JGC; De Cock PAJG
    Clin Pharmacokinet; 2021 Mar; 60(3):353-363. PubMed ID: 33030704
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens.
    Hu S; Wang T; You H; Wei S; Song H; Zhang T; Zhang D; Dong Y
    Basic Clin Pharmacol Toxicol; 2018 Nov; 123(5):594-601. PubMed ID: 29702731
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tools for the Individualized Therapy of Teicoplanin for Neonates and Children.
    Ramos-Martín V; Neely MN; Padmore K; Peak M; Beresford MW; Turner MA; Paulus S; López-Herce J; Hope WW
    Antimicrob Agents Chemother; 2017 Oct; 61(10):. PubMed ID: 28760897
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Factors on trough teicoplanin levels, associations between levels, efficacy and safety in patients with gram-positive infections.
    Wang T; Li N; Hu S; Xie J; Lei J; Wang Y; Zheng X; Xing J; Dong Y
    Int J Clin Pharmacol Ther; 2015 May; 53(5):356-62. PubMed ID: 25828639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.